The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Guselkumab Improves Active Psoriatic Arthritis

Guselkumab Improves Active Psoriatic Arthritis

January 11, 2017 • By Michele B. Kaufman, PharmD, BCGP, & Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

New research has revealed that patients with active psoriatic arthritis (PsA) and ≥3% body area of plaque psoriasis benefit from treatment with a human monoclonal antibody known as guselkumab (GUS). GUS is specific for the p19 subunit of interleukin-23 (IL-23). Patients in the Phase 2 clinical trial experienced significant improvement in joint symptoms, physical function, psoriasis, enthesitis, dactylitis and quality of life. Specifically, more than half (58%) of the patients treated with GUS experienced at least a 20% improvement in American College of Rheumatology signs and symptoms of disease (ACR20) at Week 24 compared with 18.4% of placebo-treated patients—the study’s primary endpoint (P<0.001).1

You Might Also Like
  • Rheumatology Drug Updates: Efficacy & Safety of Guselkumab, Plus FX006 for Knee OA
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
  • Guselkumab Studied to Treat RA & Plaque Psoriasis

“It is encouraging to see how well patients responded to guselkumab with respect to improvements in signs and symptoms of psoriatic arthritis as early as Week 4 and to see the improvements in health-related quality of life outcomes, such as measures of physical and mental health,” says senior author Atul Deodhar, MD, a rheumatologist at Oregon Health & Science University in Portland, in an email to The Rheumatologist.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Participants in the double-blind, placebo-controlled multicenter study received standard-of-care therapy for PsA, including tumor necrosis factor alpha (TNFα) inhibitors. Despite standard treatment, the participants had at least 3% of their body surface area covered with plaques. The investigators randomized patients (2:1) to receive either 100 mg GUS subcutaneously or placebo at Weeks 0, 4 and every eight weeks thereafter through Week 44. Only four placebo-treated patients (8.2%) and nine GUS-treated patients (9.0%) had previously received TNFα inhibitors.

If patients from either group had less than a 5% improvement from baseline in both tender joint counts and swollen joints at Week 16, they were given the option of early escape to open-label ustekinumab. At Week 24, the remaining placebo patients crossed over to receive 100 mg GUS subcutaneously, given at Week 28 and every eight weeks thereafter through Week 44. The protocol was similar to that used with the initial randomization group.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We learn something new with each of the studies using targeted biologic therapies,” explains Dr. Deodhar. “We were already aware that therapies that target IL-12 + IL-23 [ustekinumab] and those that target IL-17A were effective in treating psoriatic arthritis, but we did not know if specifically targeting IL-23 would demonstrate the same (or better) efficacy in the signs and symptoms of arthritis, enthesitis and dactylitis. Guselkumab is the first biologic therapy that specifically targets IL-23 that has been studied in PsA.” The results confirm that IL-23 plays a key role in the immunopathogenesis of psoriatic arthritis.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates

You Might Also Like:
  • Rheumatology Drug Updates: Efficacy & Safety of Guselkumab, Plus FX006 for Knee OA
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
  • Guselkumab Studied to Treat RA & Plaque Psoriasis
  • Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)